BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 30270531)

  • 1. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.
    Kandarian SC; Nosacka RL; Delitto AE; Judge AR; Judge SM; Ganey JD; Moreira JD; Jackman RW
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1109-1120. PubMed ID: 30270531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.
    Seto DN; Kandarian SC; Jackman RW
    J Biol Chem; 2015 Aug; 290(32):19976-86. PubMed ID: 26092726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.
    Cerquone Perpetuini A; Re Cecconi AD; Chiappa M; Martinelli GB; Fuoco C; Desiderio G; Castagnoli L; Gargioli C; Piccirillo R; Cesareni G
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):727-746. PubMed ID: 29781585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myostatin is a novel tumoral factor that induces cancer cachexia.
    Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
    Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A standardized herbal combination of Astragalus membranaceus and Paeonia japonica, protects against muscle atrophy in a C26 colon cancer cachexia mouse model.
    Lee SB; Lee JS; Moon SO; Lee HD; Yoon YS; Son CG
    J Ethnopharmacol; 2021 Mar; 267():113470. PubMed ID: 33068652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.
    Aulino P; Berardi E; Cardillo VM; Rizzuto E; Perniconi B; Ramina C; Padula F; Spugnini EP; Baldi A; Faiola F; Adamo S; Coletti D
    BMC Cancer; 2010 Jul; 10():363. PubMed ID: 20615237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL-6 and tumour-derived extracellular vesicles.
    Fan M; Gu X; Zhang W; Shen Q; Zhang R; Fang Q; Wang Y; Guo X; Zhang X; Liu X
    J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2724-2739. PubMed ID: 36085573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
    Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
    Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
    Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
    Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerobic and resistance training dependent skeletal muscle plasticity in the colon-26 murine model of cancer cachexia.
    Khamoui AV; Park BS; Kim DH; Yeh MC; Oh SL; Elam ML; Jo E; Arjmandi BH; Salazar G; Grant SC; Contreras RJ; Lee WJ; Kim JS
    Metabolism; 2016 May; 65(5):685-698. PubMed ID: 27085776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paeoniflorin alleviated muscle atrophy in cancer cachexia through inhibiting TLR4/NF-κB signaling and activating AKT/mTOR signaling.
    Zhu Z; Li C; Gu X; Wang X; Zhang G; Fan M; Zhao Y; Liu X; Zhang X
    Toxicol Appl Pharmacol; 2024 Mar; 484():116846. PubMed ID: 38331105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin.
    Arora GK; Gupta A; Narayanan S; Guo T; Iyengar P; Infante RE
    JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
    Fukawa T; Yan-Jiang BC; Min-Wen JC; Jun-Hao ET; Huang D; Qian CN; Ong P; Li Z; Chen S; Mak SY; Lim WJ; Kanayama HO; Mohan RE; Wang RR; Lai JH; Chua C; Ong HS; Tan KK; Ho YS; Tan IB; Teh BT; Shyh-Chang N
    Nat Med; 2016 Jun; 22(6):666-71. PubMed ID: 27135739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia.
    Lu S; Li Y; Shen Q; Zhang W; Gu X; Ma M; Li Y; Zhang L; Liu X; Zhang X
    J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):779-795. PubMed ID: 33951335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a traditional Chinese medicine-based agent for the treatment of cancer cachexia.
    Wu KC; Chu PC; Cheng YJ; Li CI; Tian J; Wu HY; Wu SH; Lai YC; Kao HH; Hsu AL; Lin HW; Lin CH
    J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2073-2087. PubMed ID: 35718751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice.
    Chrysostomou SE; Eder S; Pototschnig I; Mayer AL; Derler M; Mussbacher M; Schauer S; Zhang D; Yan D; Liu G; Hoefler G; Weichhart T; Vesely PW; Zhang L; Schweiger M
    J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):562-574. PubMed ID: 38302863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia.
    Judge SM; Wu CL; Beharry AW; Roberts BM; Ferreira LF; Kandarian SC; Judge AR
    BMC Cancer; 2014 Dec; 14():997. PubMed ID: 25539728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous Release of Tumor-Derived Factors Improves the Modeling of Cachexia in Muscle Cell Culture.
    Jackman RW; Floro J; Yoshimine R; Zitin B; Eiampikul M; El-Jack K; Seto DN; Kandarian SC
    Front Physiol; 2017; 8():738. PubMed ID: 28993738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
    Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
    Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.